{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$0.69 vs. cons $0.678",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$14.50B vs. cons $14.379B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Vyndaqel revenue",
      "prediction": "MISS",
      "answer": "pred ~$1.68B vs. cons $1.702B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 revenue",
      "prediction": "LOWER",
      "answer": "guide $59.5B-$62.5B vs. cons $61.761B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adjusted diluted EPS",
      "prediction": "LOWER",
      "answer": "guide $2.80-$3.00 vs. cons $2.939",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "2H26 COVID / cost commentary",
      "prediction": "UNCHANGED",
      "answer": "reiterate seasonal COVID caution and savings trajectory; consensus UNVERIFIED",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -2.0,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 maintained guidance below consensus should restrain revisions",
  "day5_confidence": "LOW"
}